Genmab Licenses DuoBody Platform to Novo Nordisk

News   Aug 17, 2015

 
Genmab Licenses DuoBody Platform to Novo Nordisk
 
 
 

RELATED ARTICLES

New Rare Antibody Isolation Strategy

News

A strategy for rapidly isolating rare, naturally occurring antibodies is reported this week. The strategy could aid in developing biological therapeutics and vaccines in the future.

READ MORE

Patent Plausability Case Sees BIA Intervention

News

The UK Bioindustry Association (BIA) will intervene in a court case which could have huge ramifications for UK bioscience.

READ MORE

Pioneering Method Enables Screening Millions of Human Antibodies for Rapid Therapeutic Discovery

News

A paper just published in Nature Biotechnology outlines a pioneering method of screening a person's diverse set of antibodies for rapid therapeutic discovery.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE